

# The Medical Letter<sup>®</sup>

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

**IN THIS ISSUE** (starts on next page)

**In Brief: Intravenous Ondansetron (*Zofran*)  
32 mg Withdrawn ..... p 104**

## Important Copyright Message

The Medical Letter<sup>®</sup> publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions, Site Licenses, Reprints](#)  
or call customer service at: 800-211-2769**

---

**FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter publications are protected by US and international copyright laws.  
Forwarding, copying or any other distribution of this material is strictly prohibited.  
For further information call: 800-211-2769

# The Medical Letter®

On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

Volume 54 (Issue 1406)  
December 24, 2012

[www.medicalletter.org](http://www.medicalletter.org)

## IN BRIEF

---

### **Intravenous Ondansetron (*Zofran*) 32 mg Withdrawn**

The FDA has announced that the single 32-mg IV dose of ondansetron (*Zofran*, and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it can prolong the QT interval and could possibly cause a torsades de pointes cardiac arrhythmia. For this indication, the only recommended dose of IV ondansetron is 0.15 mg/kg (maximum 16 mg/dose) every 4 hours for 3 doses. There are no changes in the recommended dosing regimens for oral ondansetron or for IV ondansetron used for prevention of postoperative nausea and vomiting.

The Medical Letter®  
On Drugs and Therapeutics

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.

**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

**EDITOR:** Jean-Marie Pflomm, Pharm.D.

**ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D.,  
Corinne Z. Morrison, Pharm.D.

**CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:**

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine

Jane P. Gagliardi, M.D., M.H.S., F.A.C.P. Duke University School of Medicine

Jules Hirsch, M.D., Rockefeller University

David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Hans Meinertz, M.D., University Hospital, Copenhagen

Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine

Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School

F. Estelle R. Simons, M.D., University of Manitoba

Neal H. Steigbigel, M.D., New York University School of Medicine

Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University

**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard

**ASSOCIATE EDITOR:** Cynthia Macapagal Covey

**EDITORIAL FELLOW:** Jennifer Y. Lin, M.D., Harvard Medical School

**MANAGING EDITOR:** Susie Wong

**ASSISTANT MANAGING EDITOR:** Liz Donohue

**PRODUCTION COORDINATOR:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona

**FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski

**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino

**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

**Subscription Services**

**Mailing Address:**

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537

**Customer Service:**

Call: 800-211-2769 or 914-235-0500

Fax: 914-632-1733

Web Site: [www.medicalletter.org](http://www.medicalletter.org)

E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**

1 year - \$98; 2 years - \$189;  
3 years - \$279. \$49.00 per year for  
students, interns, residents and  
fellows in the US and Canada.

**E-mail site license inquiries to:**

[info@medicalletter.org](mailto:info@medicalletter.org) or call  
800-211-2769 x315.

Special fees for bulk subscriptions.  
Special classroom rates are available.  
Back issues are \$12 each.  
Major credit cards accepted.

Copyright 2012. ISSN 1523-2859

